Bulletin from the extraordinary general meeting of Calliditas Therapeutics AB (publ) September 30, 2024 14:30 CET Regulatory Read more
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm September 16, 2024 15:30 CET Regulatory Read more
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei September 3, 2024 12:15 CET Regulatory Read more
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ) September 3, 2024 12:00 CET Regulatory Read more
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis July 26, 2024 08:00 CET Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) June 17, 2024 17:30 CET Regulatory Read more
Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy May 30, 2024 20:00 CET Regulatory Read more
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation May 28, 2024 08:30 CET Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) May 15, 2024 12:00 CET Regulatory Read more
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib May 6, 2024 08:00 CET Regulatory Read more
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO® March 6, 2024 08:15 CET Regulatory Read more
Calliditas Therapeutics provides business update ahead of JP Morgan conference January 8, 2024 08:15 CET Regulatory Read more
